Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Abstract Background Results of conventional induction chemotherapies in primary central nervous system lymphoma (PCNSL) need to be improved. Ibrutinib, a BTK inhibitor, and lenalidomide, an immunomodulatory drug, have shown promising results at relapse, supporting to further assess their individual...

Descripció completa

Dades bibliogràfiques

Autors principals:	Marion Alcantara, Marion Chevrier, Fabrice Jardin, Anna Schmitt, Caroline Houillier, Lucie Oberic, Olivier Chinot, Franck Morschhauser, Frédéric Peyrade, Roch Houot, Khê Hoang-Xuan, Hervé Ghesquieres, Carole Soussain
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2024-09-01
Col·lecció:	Journal of Hematology & Oncology
Matèries:	Primary central nervous system lymphoma Phase IB trial Ibrutinib Lenalidomide
Accés en línia:	https://doi.org/10.1186/s13045-024-01606-w
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!